Allogene Therapeutics ALLO Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's unrealized gains (losses) on available-for-sale securities?
- Allogene Therapeutics (ALLO) reported unrealized gains (losses) on available-for-sale securities of -$452K in Q1 2026.
- How has Allogene Therapeutics's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Allogene Therapeutics's unrealized gains (losses) on available-for-sale securities decreased by 442.4% year-over-year, from $132K to -$452K.
- What is the long-term trend for Allogene Therapeutics's unrealized gains (losses) on available-for-sale securities?
- Over 2 years (2021 to 2025), Allogene Therapeutics's unrealized gains (losses) on available-for-sale securities has grown at a -64.5% compound annual growth rate (CAGR), from -$2.84M to $358K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric represents the change in the fair value of available-for-sale debt or equity securities that has not yet been realized through a sale. It reflects unrealized gains or losses that are excluded from net income and instead reported as a component of other comprehensive income. Monitoring this figure helps investors understand the volatility and unrealized performance of the company's investment portfolio.